CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Favipiravir

法匹拉韦 杂质对照品Favipiravir Impurities

30 个杂质条目30 impurity entries

本页汇总 法匹拉韦 的 30 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 30 impurity reference standards of Favipiravir. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 法匹拉韦(Favipiravir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesAn Eco-Friendly RP-HPLC Method Development and Validation for Quantification of Favipiravir in Bulk and Tablet Dosage Form Followed by Forced Degradation Study
    Journal of chromatographic science · 2024 · Sangani MB, Patel N  ·  PMID 38266038  ·  DOI
  2. 杂质研究Impurity studiesStability Indicating High Performance Liquid Chromatography Method Development, Validation, and Characterization of Forced Degradant Product by Liquid Chromatography-Mass Spectroscopy for Molnupiravir and Favipiravir
    Journal of chromatographic science · 2025 · Pethani TM et al.  ·  PMID 40152015  ·  DOI
  3. 杂质研究Impurity studiesA liquid chromatography-tandem mass spectrometry method development for the quantification of favipiravir drug and its related impurities in rat plasma and its application to pharmacokinetic studies
    Biomedical chromatography : BMC · 2024 · Koganti K et al.  ·  PMID 38128129  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisOne-step synthesis of favipiravir from Selectfluor® and 3-hydroxy-2-pyrazinecarboxamide in an ionic liquid
    Organic & biomolecular chemistry · 2023 · Fuentes G et al.  ·  PMID 37067256  ·  DOI
  • 合成方法SynthesisScalable synthesis of favipiravir via conventional and continuous flow chemistry
    RSC advances · 2021 · Tiyasakulchai T et al.  ·  PMID 35493228  ·  DOI

法匹拉韦 —— 原料药与杂质对照品Favipiravir — drug substance & impurities

共 31 个条目(含原料药本体)31 items incl. the drug substance
Favipiravir structure
原料药 APIAPI
法匹拉韦Favipiravir
Favipiravir
CAS No.259793-96-9
Chemical FormulaC5H4FN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 1 structure
1
法匹拉韦杂质1Favipiravir Impurity 1
Favipiravir Impurity 1
CAS No.356783-16-9
Chemical FormulaC5HCl2N3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 2 structure
2
法匹拉韦杂质2Favipiravir Impurity 2
Favipiravir Impurity 2
CAS No.356783-28-3
Chemical FormulaC5HF2N3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 3 structure
3
法匹拉韦杂质3Favipiravir Impurity 3
Favipiravir Impurity 3
CAS No.1137606-74-6
Chemical FormulaC5H2FN3O·C12H23N
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 4 structure
4
法匹拉韦杂质4Favipiravir Impurity 4
Favipiravir Impurity 4
CAS No.259793-90-3
Chemical FormulaC5H4ClN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 5 structure
5
法匹拉韦杂质5Favipiravir Impurity 5
Favipiravir Impurity 5
CAS No.1079990-21-8
Chemical FormulaC5H3FN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 9 structure
9
法匹拉韦杂质9Favipiravir Impurity 9
Favipiravir Impurity 9
CAS No.440124-25-4
Chemical FormulaC5HBrClN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 10 structure
10
法匹拉韦杂质10Favipiravir Impurity 10
Favipiravir Impurity 10
CAS No.259793-88-9
Chemical FormulaC5H4BrN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 11 structure
11
法匹拉韦杂质11Favipiravir Impurity 11
Favipiravir Impurity 11
CAS No.6863-74-7
Chemical FormulaC5H2ClN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 12 structure
12
法匹拉韦杂质12Favipiravir Impurity 12
Favipiravir Impurity 12
CAS No.356783-46-5
Chemical FormulaC5H2FN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 14 structure
14
法匹拉韦杂质14Favipiravir Impurity 14
Favipiravir Impurity 14
CAS No.356783-49-8
Chemical FormulaC5HClFN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 15 structure
15
法匹拉韦杂质15Favipiravir Impurity 15
Favipiravir Impurity 15
CAS No.1492021-29-0
Chemical FormulaC5H4FN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 20 structure
20
法匹拉韦杂质20Favipiravir Impurity 20
Favipiravir Impurity 20
CAS No.21874-61-3
Chemical FormulaC6H5BrN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 21 structure
21
法匹拉韦杂质21Favipiravir Impurity 21
Favipiravir Impurity 21
CAS No.1257072-34-6
Chemical FormulaC5HBrClN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 23 structure
23
法匹拉韦杂质23Favipiravir Impurity 23
Favipiravir Impurity 23
CAS No.55321-99-8
Chemical FormulaC5H5N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 26 structure
26
法匹拉韦杂质26Favipiravir Impurity 26
Favipiravir Impurity 26
CAS No.81411-78-1
Chemical FormulaC5H3N3O
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 27 structure
27
法匹拉韦杂质27Favipiravir Impurity 27
Favipiravir Impurity 27
CAS No.356783-29-4
Chemical FormulaC5H3F2N3O
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 28 structure
28
法匹拉韦杂质28Favipiravir Impurity 28
Favipiravir Impurity 28
CAS No.2180081-37-0
Chemical FormulaC5HBrClN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 29 structure
29
法匹拉韦杂质29Favipiravir Impurity 29
Favipiravir Impurity 29
CAS No.1351238-11-3
Chemical FormulaC5HBr2N3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 31 structure
31
法匹拉韦杂质31Favipiravir Impurity 31
Favipiravir Impurity 31
CAS No.2305633-62-7
Chemical FormulaC5H2BrN3O
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 32 structure
32
法匹拉韦杂质32Favipiravir Impurity 32
Favipiravir Impurity 32
CAS No.55557-52-3
Chemical FormulaC5H2ClN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 33 structure
33
法匹拉韦杂质33Favipiravir Impurity 33
Favipiravir Impurity 33
CAS No.1207614-48-9
Chemical FormulaC5H2FN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 37 structure
37
法匹拉韦杂质37Favipiravir Impurity 37
Favipiravir Impurity 37
CAS No.259794-01-9
Chemical FormulaC5H4FN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 38 structure
38
法匹拉韦杂质38Favipiravir Impurity 38
Favipiravir Impurity 38
CAS No.356783-47-6
Chemical FormulaC5H4FN3O
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 39 structure
39
法匹拉韦杂质39Favipiravir Impurity 39
Favipiravir Impurity 39
CAS No.13301-04-7
Chemical FormulaC6H4Br2N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 45 structure
45
法匹拉韦杂质45Favipiravir Impurity 45
Favipiravir Impurity 45
CAS No.38275-57-9
Chemical FormulaC5H2BrN3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 46 structure
46
法匹拉韦杂质46Favipiravir Impurity 46
Favipiravir Impurity 46
CAS No.13238-84-1
Chemical FormulaC8H12N2
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 47 structure
47
法匹拉韦杂质47Favipiravir Impurity 47
Favipiravir Impurity 47
CAS No.259794-06-4
Chemical FormulaC7H7BrN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 48 structure
48
法匹拉韦杂质48Favipiravir Impurity 48
Favipiravir Impurity 48
CAS No.2091074-00-7
Chemical FormulaC5HCl2N3
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 50 structure
50
法匹拉韦杂质50Favipiravir Impurity 50
Favipiravir Impurity 50
CAS No.1513-65-1
Chemical FormulaC5H3F2N
Purity>95%询价On request
10mg25mg50mg100mg
Favipiravir Impurity 51 structure
51
法匹拉韦杂质51Favipiravir Impurity 51
Favipiravir Impurity 51
CAS No.859064-07-6
Chemical FormulaC6H6N2O3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

法匹拉韦 —— 研究文献与合成路线Favipiravir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 法匹拉韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Favipiravir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability Indicating High Performance Liquid Chromatography Method Development, Validation, and Characterization of Forced Degradant Product by Liquid Chromatography-Mass Spectroscopy for Molnupiravir and Favipiravir
    Pethani TM, Sangani M, Santoki PS · Journal of chromatographic science · 2025
  2. A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling
    Marzouk HM, Rezk MR, Gouda AS, et al. · Microchemical journal : devoted to the application of microtechniques in all branches of science · 2022 · 被引 47cited 47
  3. Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC-MS method
    Vemuri DK, Gundla R, Konduru N, et al. · Biomedical chromatography : BMC · 2022 · 被引 13cited 13
  4. Structural Elucidation of Alkali Degradation Impurities of Favipiravir from the Oral Suspension: UPLC-TQ-ESI-MS/MS and NMR
    Patel R, Dube A, Solanki R, et al. · Molecules (Basel, Switzerland) · 2022 · 被引 10cited 10
  5. An Eco-Friendly RP-HPLC Method Development and Validation for Quantification of Favipiravir in Bulk and Tablet Dosage Form Followed by Forced Degradation Study
    Sangani MB, Patel N · Journal of chromatographic science · 2024 · 被引 4cited 4
  6. A quality-by-design optimized LC method for navigating degradation kinetics and quantification of favipiravir in the presence of degradation products and manufacturing impurities
    Ibrahim AE, Farouk M, Alamir SG, et al. · BMC chemistry · 2025 · 被引 2cited 2

合成路线文献Synthetic-route papers

  1. Green synthesis of structural analogs of favipiravir
    Haghpanah M, Molla Ebrahimlo AR, Moshtaghi Zonouz A · RSC advances · 2025
  2. Three-Step Process for the Synthesis of Favipiravir for Covid-19
    Swarnayu B, DR MA, basireddy Sr · 2023
  3. An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
    Karatas H, Hanashalshahaby EHA, Catal U, et al. · Chemicke zvesti · 2023

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

法匹拉韦 杂质谱研究要点Favipiravir — impurity profiling notes

下面这些是拿到 法匹拉韦 的 31 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 31 impurity entries for Favipiravir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances